Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Array Biopharma Inc Study Shows Asthma Candidate ARRY-502 Improves Lung Function-DJ


Tuesday, 23 Jul 2013 06:54am EDT 

Dow Jones reported that Array Biopharma Inc said a study showed its drug candidate, ARRY-502, improved a measure of lung function for people with mild to moderate persistent allergic asthma. Shares recently jumped 17% to $6.49 premarket as Array said results from a Phase 2 trial indicated ARRY-502 achieved the primary endpoint of significantly improving pre-bronchodilator forced expiratory volume in one second. ARRY-502 also was well tolerated with fewer side effects, when compared to a placebo. Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and asthma quality of life questionnaires. 

Company Quote

4.86
 --
19 Dec 2014